Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 15/20 | 1.00 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401416 | 0.94 | CHRNB2 (0.88) | CHRNB2CHRNA4HTR3AHTR3EHTR3B | |
| SCHEMBL2617751 | 0.94 | CHRNB2 (0.88) | CHRNB2CHRNA4HTR3AHTR3EHTR3B | |
| SCHEMBL9393877 | 0.88 | CHRNB2 (0.79) | CHRNB2CHRNA4HTR3ACHRNB4CHRNA3 | |
| SCHEMBL5312452 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL26093287 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4HTR3AHTR3EHTR3B | |
| Trifluoroacetic Acid SCHEMBL2119009 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4HTR3AHTR3EHTR3B | |
| SCHEMBL6350420 | 0.81 | CHRNB2 (0.67) | CHRNB2CHRNA4 | |
| SCHEMBL231910 | 0.80 | CHRNB2 (0.68) | CHRNB2CHRNA4ADRB1 | |
| SCHEMBL3063508 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA4 | |
| SCHEMBL6350419 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825189-B1 | TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION | NEUROSEARCH A/S (DK) | 2004-11-30 | — | — | US | claimed |
| EP-1027336-B1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH AS (DK) | 2004-10-06 | — | — | EP | claimed |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | NEUROSEARCH A/S | 2004-04-15 | — | — | US | claimed |
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-6897219-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2005-05-24 | — | — | US | disclosed |
| US-6825189-B1 | TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION | NEUROSEARCH A/S (DK) | 2004-11-30 | — | — | US | disclosed |
| EP-1027336-B1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH AS (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | NEUROSEARCH A/S | 2004-04-15 | — | — | US | disclosed |
| CN-1131211-C | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH AS (DK) | 2003-12-17 | — | — | CN | disclosed |
| CN-1277604-A | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH AS (DK) | 2000-12-20 | — | — | CN | disclosed |
| EP-1027336-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021834-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | CHRNB2 2866/4885CHRNA4 1765/4885HTR3A 3772/4885 |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | OGFR, CBR3, OGFRL1 | CHRNB2 700/4885CHRNA4 1019/4885HTR3A 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.